Cargando…

Early initiation of rivaroxaban after reperfusion therapy for stroke patients with nonvalvular atrial fibrillation

BACKGROUND: The optimal timing of initiating oral anticoagulants after reperfusion therapy for ischemic stroke is unknown. Factors related to early initiation of rivaroxaban and differences in clinical outcomes of stroke patients with nonvalvular atrial fibrillation (NVAF) who underwent reperfusion...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koge, Junpei, Yamagami, Hiroshi, Toyoda, Kazunori, Yasaka, Masahiro, Hirano, Teruyuki, Hamasaki, Toshimitsu, Nagao, Takehiko, Yoshimura, Shinichi, Fujishige, Masahito, Tempaku, Akira, Uchiyama, Shinichiro, Mori, Etsuro, Koga, Masatoshi, Minematsu, Kazuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985957/ https://www.ncbi.nlm.nih.gov/pubmed/35385480 http://dx.doi.org/10.1371/journal.pone.0264760

Ejemplares similares

Rivaroxaban administration after acute ischemic stroke: The RELAXED study
por: Yasaka, Masahiro, et al.
Publicado: (2019)

Real-world outcomes of rivaroxaban treatment in elderly Japanese patients with nonvalvular atrial fibrillation
por: Kitazono, Takanari, et al.
Publicado: (2019)

Bilateral carotid artery dissection due to Eagle syndrome in a patient with vascular Ehlers-Danlos syndrome: a case report
por: Ikenouchi, Hajime, et al.
Publicado: (2020)

Patient satisfaction after switching from warfarin to apixaban in patients with nonvalvular atrial fibrillation: AGAIN study
por: Koretsune, Yukihiro, et al.
Publicado: (2017)

Etiology and Outcome of Ischemic Stroke in Patients With Renal Impairment Including Chronic Kidney Disease: Japan Stroke Data Bank
por: Miwa, Kaori, et al.
Publicado: (2022)

Practical “1-2-3-4-Day” Rule for Starting Direct Oral Anticoagulants After Ischemic Stroke With Atrial Fibrillation: Combined Hospital-Based Cohort Study
por: Kimura, Shunsuke, et al.
Publicado: (2022)

Impact of three major risk factors on clinical outcomes in patients with nonvalvular atrial fibrillation receiving rivaroxaban: Sub‐analysis from the XAPASS study
por: Ikeda, Takanori, et al.
Publicado: (2022)

Evaluation of Workflow Delays in Stroke Reperfusion Therapy: A Comparison between the Year-Long Pre-COVID-19 Period and the with-COVID-19 Period
por: Yoshimoto, Takeshi, et al.
Publicado: (2022)

Blind Exchange With Mini-Pinning Technique Using the Tron Stent Retriever for Middle Cerebral Artery M2 Occlusion Thrombectomy in Acute Ischemic Stroke
por: Yoshimoto, Takeshi, et al.
Publicado: (2021)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Application of plasma metabolome for monitoring the effect of rivaroxaban in patients with nonvalvular atrial fibrillation
por: Zhao, Mindi, et al.
Publicado: (2022)

Atherosclerotic Components in Thrombi Retrieved by Thrombectomy for Internal Carotid Artery Occlusion Due to Large Artery Atherosclerosis: A Case Report
por: Eto, Futoshi, et al.
Publicado: (2021)

THrombolysis for Acute Wake-up and unclear-onset Strokes with alteplase at 0·6 mg/kg (THAWS) Trial
por: Koga, Masatoshi, et al.
Publicado: (2014)

Clinical utility of rivaroxaban in stroke prevention associated with nonvalvular atrial fibrillation – patient considerations
por: Ahrens, Ingo, et al.
Publicado: (2014)

Post-marketing surveillance on the long-term use of dabigatran in Japanese patients with nonvalvular atrial fibrillation: Preliminary report of the J-dabigatran surveillance
por: Inoue, Hiroshi, et al.
Publicado: (2016)

Atrial Fibrillation After Ischemic Stroke Detected by Chest Strap-Style 7-Day Holter Monitoring and the Risk Predictors: EDUCATE-ESUS
por: Miyazaki, Yuichi, et al.
Publicado: (2021)

Anticoagulation Intensity of Rivaroxaban for Stroke Patients at a Special Low Dosage in Japan
por: Okata, Takuya, et al.
Publicado: (2014)

Efficacy and Safety of Prasugrel by Stroke Subtype: A Sub-Analysis of the PRASTRO-I Randomized Controlled Trial
por: Kitazono, Takanari, et al.
Publicado: (2021)

Incidence and characteristics of major bleeding among rivaroxaban users with renal disease and nonvalvular atrial fibrillation
por: Patel, Manesh R., et al.
Publicado: (2018)

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
por: Martinez, Brandon K., et al.
Publicado: (2018)

Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation
por: Brown, Joshua D., et al.
Publicado: (2016)

Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy
por: Alberts, Mark J., et al.
Publicado: (2022)

Characteristics of Japanese Patients with Nonvalvular Atrial Fibrillation on Anticoagulant Treatment: A Descriptive Analysis of J-dabigatran Surveillance and JAPAF Study
por: Koretsune, Yukihiro, et al.
Publicado: (2019)

Long-Term Effect of Pravastatin on Carotid Intima–Media Complex Thickness: The J-STARS Echo Study (Japan Statin Treatment Against Recurrent Stroke)
por: Koga, Masatoshi, et al.
Publicado: (2018)

Acute Stroke Care in the With-COVID-19 Era: Experience at a Comprehensive Stroke Center in Japan
por: Koge, Junpei, et al.
Publicado: (2021)

Twenty-Year Change in Severity and Outcome of Ischemic and Hemorrhagic Strokes
por: Toyoda, Kazunori, et al.
Publicado: (2021)

Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
por: Laliberté, François, et al.
Publicado: (2015)

Comparative Assessment of the Anticoagulant Activity of Rivaroxaban and Dabigatran in Patients With Nonvalvular Atrial Fibrillation: A Noninterventional Study
por: Tsantes, Argirios E., et al.
Publicado: (2016)

Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US
por: Miller, Jeffrey D, et al.
Publicado: (2016)

Reduced-Dose Rivaroxaban Is Associated with Lower All-Cause Mortality in Older Patients with Nonvalvular Atrial Fibrillation
por: Chiou, Wei-Ru, et al.
Publicado: (2023)

Prior Anticoagulation and Short‐ or Long‐Term Clinical Outcomes in Ischemic Stroke or Transient Ischemic Attack Patients With Nonvalvular Atrial Fibrillation
por: Tokunaga, Keisuke, et al.
Publicado: (2019)

Rivaroxaban concentrations in acute stroke patients with different dosage forms
por: Wada, Shinichi, et al.
Publicado: (2019)

Consensus Guides on Stroke Thrombolysis for Anticoagulated Patients from Japan: Application to Other Populations
por: Toyoda, Kazunori, et al.
Publicado: (2018)

Factors Associated with Intima-Media Complex Thickness of the Common Carotid Artery in Japanese Noncardioembolic Stroke Patients with Hyperlipidemia: The J-STARS Echo Study
por: Wada, Shinichi, et al.
Publicado: (2018)

Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
por: Laliberté, François, et al.
Publicado: (2015)

Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: The SAMURAI‐NVAF Study
por: Toyoda, Kazunori, et al.
Publicado: (2015)

Routine Coagulation Tests in Patients With Nonvalvular Atrial Fibrillation Under Dabigatran and Rivaroxaban Therapy: An Affordable and Reliable Strategy?
por: Silva, Vanessa M., et al.
Publicado: (2019)

Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin
por: Coleman, Craig I., et al.
Publicado: (2021)

Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes
por: Weir, Matthew R., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_04espln4367dtlblr7i078fakd